Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 14,470

Document Document Title
WO/2018/116072A1
The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compo...  
WO/2018/117493A1
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. According to the present invention, the compound is used in an organic material layer, preferably in a light-emitting layer, ...  
WO/2018/119444A1
The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formul...  
WO/2018/111707A1
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).  
WO/2018/109643A1
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula...  
WO/2018/109204A1
Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure (I).  
WO/2018/112084A1
The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of For...  
WO/2018/109496A2
The present invention relates to a process for the preparation compounds of Formula (I): Formula (I) wherein X, Z, Q, Ar, R1, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation o...  
WO/2018/109649A1
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and...  
WO/2018/109786A1
The present invention provides novel polymorphs of (3S,11aR)-N-[(2,4-difluorophenyl) methyl]-6- hydroxy-3-methyl-5, 7-dioxo-2, 3,5,7, 11, 11a-hexahydro[1, 3]oxazolo[3, 2-a]pyrido[1, 2-d]pyrazine-8-carboxamide including sodium and potassi...  
WO/2018/109097A1
The invention provides novel compounds having RIP1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.  
WO/2018/112094A1
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...  
WO/2018/109646A1
The present invention relates to a compound which is (R)-3-(1,4- dimethyl-1 H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3- dihydropyrido[2,3-f][l,4]oxazepin-4(5H)-yl)methyl)-4-methylp henyl) propanoic acid (I), or a pharmaceutica...  
WO/2018/109647A1
The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I).  
WO/2018/108084A1
Provided is a compound containing a tricyclic heteroaryl group. Specifically, provided are a compound (the definitions of groups are as stated in the description) having a structure as shown in formula (I), a pharmaceutical composition c...  
WO/2018/104766A1
The present invention relates to compounds of Formula (I), and Formula (II), wherein B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH2)2-triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents indepe...  
WO/2018/077944A3
The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds,...  
WO/2018/102485A1
The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and R7 are as defined herein. The present invention also relates to...  
WO/2018/095839A1
The present invention relates to bridged triarylamines according to a defined formula. Said compounds are suitable for use in electronic devices. The invention also relates to methods for preparing said compounds and to electronic device...  
WO/2018/096159A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmace...  
WO/2018/092916A1
A compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, ring A represents a monocyclic or bicyclic heterocyclic ring which may be substituted by a hydroxy group or the like and has 5...  
WO/2018/093949A1
Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and comp...  
WO/2018/093946A1
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful ...  
WO/2018/005192A9
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/093947A1
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful ...  
WO/2018/087022A1
The invention relates to dibenzofurane compounds which are substituted with carbazole compounds, in particular for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a method for produ...  
WO/2018/087677A1
The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: (I). Also provided are methods of making the compounds of Formula (I) and their methods of use.  
WO/2018/089357A1
The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ...  
WO/2018/064632A8
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  
WO/2018/085367A1
Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.  
WO/2018/011527A9
The present invention relates to reagents for reversibly protecting biological molecules. In particular, it relates to compounds derived from azaisotoic anhydride and the uses of same for protecting biological molecules, particularly enz...  
WO/2018/078097A1
A crystalline form of (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5 ,6,7-tetrahydropyrazolo[1,5-α]pyrazin-3-yl)cyclohexanecarbo xamide, pharmaceutical compositions containing it and its use in therapy.  
WO/2018/042362A9
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present ...  
WO/2018/077944A2
The present invention provides triazolone compounds compounds of general formula (I) : (I), in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, 5 intermediate compounds useful for preparing said com...  
WO/2018/079759A1
The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt of the compound. The present invention relates to: a compound represented by formula (I) or a pharmaceutically acceptable s...  
WO/2018/073838A1
The present invention relates to a pyridinium oxazole dyad scaffold of formula (I) and a process for the preparation thereof. The present invention further discloses a pyridine compound of formula (II) which is used for the preparation o...  
WO/2018/074390A1
Provided are: a novel compound having a P2X7 receptor inhibitory activity; and a pharmaceutical composition having a P2X7 receptor inhibitory activity. A compound represented by formula (I) (wherein Z1 represents C(R4) or the like; R4 re...  
WO/2018/075908A1
The disclosure provides an ophthalmic formulation comprising a bromodomain inhibitor, a polar aprotic solvent (e.g., dimethyl sulfoxide (DMSO)), polysorbate, salt, and Captisol, as well as a method of treating or preventing ophthalmic in...  
WO/2018/067423A1
Compounds of general formula (la), compounds of general formula (la'), compounds of general formula (lb), compounds of general formula (lb'), compounds of general formula (I), compounds of general formula (Ι'), and their pharmaceuticall...  
WO/2018/064632A1
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...  
WO/2018/059537A1
The present invention relates to a diazaspiro[5.5]undecane derivative and a use thereof. The derivative is a compound represented by general formula (I) or a stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, e...  
WO/2018/060742A1
The present invention relates to a class of substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30)...  
WO/2017/214423A8
In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed here...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/057884A1
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further rel...  
WO/2018/055524A1
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.  
WO/2018/057588A1
Disclosed are chemical entities which are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, E, n and Z are as defined herein. These chemical entities are useful as inhibitors of the PAR-2 sig...  
WO/2018/051877A1
The present invention addresses the problem of providing an organic pigment having stronger absorption in the long wavelength region. The problem can be solved by providing: a compound represented by formula (I) (In the formula, X1, X2, ...  
WO/2018/051239A1
The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.  
WO/2018/050584A1
The invention relates to spirobifluorene derivatives which are substituted with electrone transport groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to t...  

Matches 501 - 550 out of 14,470